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Although colon cancer is the third most common cause of cancer-related death worldwide, the prevalence of
gastroenteropancreatic neuroendocrine tumours (GEP-NETs) remains rare. To date, very few cases of GEP-NETs
within Meckel’s diverticulum and synchronous colorectal cancer have been reported. Although the coexistence
of these two tumour types is uncommon, it is important to be aware of their disease patterns. We present a rare
case of a patient with an intestinal GEP-NET arising in Meckel’s diverticulum coexisting with metastatic colon
adenocarcinoma, and we discuss the clinical manifestations and the diagnostic procedures and treatment modalities
used. This case report underlines the importance of being aware of this particular coexistence, as well as the unlikely
metastatic spread of GEP-NETs and the importance of a multidisciplinary approach to cancer treatment. Finally,
individualizing the treatment according to the stages of the primaries will result in durable cancer control, particularly
in synchronous double malignancy.
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Neuroendocrine gastroenteropancreatic tumours (GEP-
NETs) constitute a heterogeneous group of genetically
diverse neoplasms arising from the secretory cells of the
neuroendocrine system, with the primary tumours lo-
cated in the digestive tract [1]. Their incidence is now
estimated to be 2 to 5/100,000/year, but this is probably
an underestimate. Most commonly, the primary lesion is
located in the gastric mucosa, the small and large intes-
tines, the rectum and the pancreas [2]. The development
of a second primary malignancy in patients with these
tumours is uncommon, but it has been described. How-
ever, coexistence of colon adenocarcinoma and intestinal
GEP-NET arising in a Meckel’s diverticulum is very rare
and represents diagnostic and therapeutic challenge [3].
We report a case of a patient with GEP-NET in Meckel’s
diverticulum synchronous with metastatic colon cancer,
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unless otherwise stated.and discuss the clinical manifestations as well as the
diagnostic procedures and treatment modalities used.Case presentation
A 63-year-old man presented at our hospital with abdominal
distension and diarrhoea 1 month before hospital admission.
Apart from elevated serum γ-glutamyltranspeptidase (233
U/L; normal range, 9 to 35 U/L), carcinoembryonic antigen
(CEA) (89.3 ng/ml; range, 0 to 5 ng/ml), carbohydrate anti-
gen 19-9 (CA 19-9) (2,052 U/ml; range, 0 to 37 U/ml) and
hepatomegaly, all other systems and laboratory findings
were normal. A colonoscopy revealed intraluminal stenosis
with a reddish, irregularly shaped mass located in the as-
cending colon, 15.5 cm from the ileocaecal valve, so biopsy
specimens were obtained. An open right hemicolectomy
with ileotransverse anastomosis was performed. Intraopera-
tively, the interior surface of the colon demonstrated an
invasive, exophytic, crater-like tumour. The clinical and
pathological information about the patient is summarized
in Table 1. A microscopic examination showed an infil-
trating tumour of the ascending colon, measuring 3.5 ×
3.0 × 2.6 cm with extension into the pericolic fat and
mesenteric lymphatics (involving 10 of 23 regional lymphl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical and pathological data of the patienta
Colon
adenocarcinoma
Neuroendocrine
tumour
Tumour size 3.5 × 3.0 × 2.6 cm 3 × 2 × 2 cm
Fat tissue invasion + −
Lymph node invasion + (10/23) − (0/23)
Perineural invasion + −
Vascular invasion + −
Lymphatic vessel invasion + +
Muscularis propria invasion + +
Serosal invasion + −
Resection margins − −
Tumour necrosis − −
CKAE1/AE3 + +
CgA + +
KRAS − Not applicable
Synaptophysin + +
Ki-67 60% 3%
Mitoses/10 hpf >20 ≤2
Grade of the cancer High grade (G3) Low grade (G1)
Astler-Coller classification
[4]
D Not applicable
TNM stage pT3pN2bpM1a pT3pN0pM0
AJCC clinical stage [5] IVA IIB
aAJCC, American Joint Committee on Cancer; CgA, Chromogranin A; CKAE1/
AE3, Cytokeratin AE1/AE3; hpf, High-power fields; Ki-67, Antigen Ki-67; KRAS,
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; TNM, Tumour, node,
metastasis classification of malignant tumours.
Katalinic et al. World Journal of Surgical Oncology 2014, 12:358 Page 2 of 7
http://www.wjso.com/content/12/1/358nodes), with neural and vascular invasion. Histological
sections revealed a connection to the intestinal mucosa
with extension into the underlying muscularis propria, but
without serosal affection. The tubular resection margins
were without tumour involvement. The immunohisto-
chemical stains (cytokeratin AE1/AE3 (CKAE1/AE3)–
positive, chromogranin A (CgA)–positive, synaptophysin-
positive, antigen Ki-67 (Ki-67) at 60%, with >20 mitoses/
10 high-power fields (hpf)) supported the diagnosis of a
metastatic, poorly differentiated form of high-grade colon
adenocarcinoma (grade G3, pT3pN2bpM1a, Astler-Coller
classification D [4], American Joint Committee on Cancer
(AJCC) stage IVA [5]) (Figure 1). Genetic testing for muta-
tions in codons 12 or 13 of the KRAS gene was negative.
Moreover, a mass in Meckel’s diverticulum, 8.7 cm prox-
imal to the ileocaecal valve, was encountered. The histo-
logical examination revealed a firm, grey-white tumour
composed of neoplastic neuroendocrine cells in the sub-
mucosa arranged in a nesting pattern measuring 3 × 2 ×
2 cm. There was penetration of the muscular layer
and lymphatic vessels, but without serosal, neural or
vascular invasion. The resection margins were free of
tumour. Immunohistochemical staging confirmed awell-differentiated, low-grade GEP-NET (low grade
(grade G1), pT3pN0pM0, AJCC stage IIB, CKAE1/
AE3–positive, CgA–positive, synaptophysin-positive,
Ki-67 at 3%, with 2 mitoses/10 hpf, without necrosis)
(Figure 2) according to World Health Organisation
and European Neuroendocrine Tumour Society guidelines
[6]. There was evidence of multiple hepatic metasta-
ses from colon carcinoma, based on abdominal ultra-
sonography, computed tomography (CT) (Figure 3)
and liver biopsy specimens. The postoperative indium-
111-diethylenetriaminepentaacetic acid-D-phenylalanine-
octreotide scintigraphy result was negative.
The patient was seen by a medical oncologist with a
view to starting chemotherapy. Because there was only
evidence of colon cancer metastases, we decided to start
with a FOLFIRI (folinic acid, fluorouracil, irinotecan)
chemotherapy regimen, which has been reported to in-
duce major tumour responses in 40% to 50% of patients
with stage IV colon cancer [7-9]. Our patient has re-
ceived 22 cycles of chemotherapy as of this writing, and
he tolerates the treatment very well. He was in an excel-
lent general condition with good performance status and
without any sign of tumour progression or additional
metastases 11 months after the diagnosis.
Discussion
Meckel’s diverticulum is a vestigial remnant of the
omphalomesenteric duct. It is the most common em-
bryonic malformation of the gastrointestinal tract and
is present in approximately 2% of the population, with
men experiencing symptoms more frequently than women
[10]. Its prevalence is three to five times higher in men
than in women. Only 2% of cases are symptomatic, and
these usually are children [11]. The condition was first de-
scribed by Fabricius Hildanus in the 16th century and was
later named after Johann F Meckel, who explained the em-
bryologic origin of this entity in 1809 [12]. As the ompha-
lomesenteric duct is made up of pluripotent cell lining,
Meckel’s diverticulum may harbour embryonic remnants
of other tissues. Heterotopic rests of gastric or intestinal
mucosa and pancreatic tissue are seen in most cases [11].
The majority of Meckel’s diverticula remain asymptomatic
throughout life. In general, they are discovered accidentally
during different surgical procedures. The main complica-
tions associated with Meckel’s diverticulum are bleeding,
ulceration, inflammation, perforation, ileus, intussuscep-
tion or neoplastic transformation. However, tumours asso-
ciated with Meckel’s diverticula occur with a frequency of
1% to 5% [13], and most of them are found incidentally
during surgery [14]. Most of them are benign tumours,
such as adenomas, leiomyomas, angiomas and lipomas.
Malignant neoplasms mainly include gastric adenocarcin-
omas, sarcomas and, rarely, gastrointestinal stromal tu-
mours and different types of NETs [3].
Figure 1 Histological and immunohistochemical stains of colon adenocarcinoma. (a) Solid tumour nests and large polygonal cells
(haematoxylin and eosin stain; original magnification, ×400). Immunohistochemical stains reveal positive findings for synaptophysin (b) (original
magnification, ×400), cytokeratin AE1/AE3 (c) (original magnification, ×400) and chromogranin A (d) (original magnification, ×400). (e) Antigen
Ki-67 immunostaging was positive in 60% of tumour cells (original magnification, ×400).
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crine system and may originate from almost any location
in the human body. They are most commonly found in
the gastrointestinal tract (such as GEP-NETs) and the
respiratory system. As neuroendocrine phenotypes and
genetics have become better understood, the definitionFigure 2 Histological and immunohistochemical stains of Meckel’s
(haematoxylin and eosin stain; original magnification, ×400). Tumour cel
magnification, ×400), cytokeratin AE1/AE3 (c) (original magnification, ×4
Ki-67 immunostaging was positive in 3% of tumour cells. (original magnificatiof neuroendocrine cells has changed and is now accepted as
referring to cells with neuromodulator, neuropeptide or
neurotransmitter hormone production; dense-core secretory
granules; and absence of axons and synapses. GEP-NETs
have attracted much attention in recent years because they
are often slow-growing neoplasms which are relatively easydiverticulum. (a) Moderately differentiated neuroendocrine tumour
ls show cytoplasmic staining for synaptophysin (b) (original
00) and chromogranin A (d) (original magnification, ×400). (e) Antigen
on, ×400).
Figure 3 Radiological evaluation of liver metastases. (a) Ultrasound. (b) Unenhanced computed tomographic scan.
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ally improved symptom control, thus offering different tar-
geted therapies for metastatic or inoperable disease [1]. This
kind of rare cancer is usually diagnosed because of symp-
toms related to the overproduction of hormones by the tu-
mours, and/or because of complications related to the
presence of the tumour mass, and/or as an incidental find-
ing during imaging or surgical procedures [15]. Depending
on whether secreted hormone is detectable and associated
symptoms are present, GEP-NETs can be divided into ‘func-
tioning’ and ‘nonfunctioning’ subtypes. Functioning tumours
are slow-growing tumours, and morbidity often results from
the secreted hormone (or hormones) rather than the
tumour mass. In cases of nonfunctioning tumours, it is
accepted that there may be secreted, but as yet un-
detectable, hormones. These nonfunctioning tumours
tend to be more aggressive with symptoms of tumour
bulk [1].
In the past, the phenomenon of multiple primary can-
cers was considered a medical curiosity. As anticipated,
multicentric cancers in a single organ, in paired organs
or in contiguous tissues are now known to occur with
increasing frequency. Generally, they fall into two cat-
egories: (1) synchronous, in which the tumours occur at
the same time; and (2) metachronous, in which the tu-
mours follow in sequence. In the 1930s, Warren and
Gates [16], in a study of 1,078 autopsies of cancer pa-
tients, revealed that 40 patients, or 3.7%, had either oc-
cult or clinically apparent second primary cancers. The
data indicate that, in a person who is genetically pre-
disposed to develop cancer, he or she will more often
develop it earlier in life than a person who develops
cancer sporadically. The precise pathogenesis of sec-
ondary cancers associated with NETs remains unclear
and quite complex, with genetic, environmental, hor-
monal, medical treatment–related and gender-specific
factors, as well as interactions thereof, undoubtedly
playing roles [17].According to a previous study, gastrin and cholecysto-
kinin were associated with NETs; this resulted in tissue
growth in the gastrointestinal tract and carcinogenesis
that led to colorectal and gastric cancers [18]. In addition,
other authors have reported that NETs are associated with
a high risk of a secondary gastrointestinal malignancy.
They studied 96 patients with NETs and found that
14 patients had a NET and a second primary malig-
nancy [19]. In patients known to have NETs, the pos-
sibility of a hypersecretion syndrome, such as the
paraneoplastic or carcinoid syndrome, always has to
be strongly considered. In a study of NETs, excluding
carcinoid tumours, Vilallonga et al. [20] found that 5
of 2,155 colorectal cancer patients were identified,
and all of the patients presented with a paraneoplastic
or carcinoid syndrome. However, our patient had no
such symptoms. Regardless of this, we cannot rule
out the possibility of secreted peptides or hormones
in the plasma at very low concentrations not associ-
ated with clinical symptoms, or, if there were secreted
peptides, they were not associated with clinical ef-
fects. As NETs are normally diagnosed after the re-
sults of histological evaluation of primary tumours or
metastases are obtained, imaging is usually used for
disease staging and further therapy planning. CT,
magnetic resonance imaging and somatostatin recep-
tor nuclear imaging, using either single-photon emission
CT or positron emission tomography (PET) modalities,
seems particularly effective in localizing the primary
tumour and its metastases [21,22].
Surgery remains the best method of treatment for
NETs, regardless of their localization. It is the preferred
option for patients with resectable disease, but palliation
with tumour debulking, chemotherapy and targeted radio-
nuclide therapy is often needed. For localized disease, only
surgery provides the possibility of complete remission
[23,24]. However, metastases to the regional lymph nodes
or distant parenchymal micrometastases may be present
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apy with chemoradiotherapy in disseminated NETs has
not been completely evaluated. In our case, the patient did
not have a secretory NET, paraneoplastic symptoms or
signs or any ectopic secretion of hormones. However, in
patients with somatostatin receptor–positive NETs, som-
atostatin analogues given subcutaneously or intramuscu-
larly (octreotide LAR given in doses of 10, 20 or 30 mg
every 4 weeks as a deep intramuscular injection or lanreo-
tide given in doses of 60, 90 or 120 mg every 4 weeks as a
deep subcutaneous injection) alleviate symptoms by
blocking hormone release [22,25]. Chemotherapy is not
considered a part of first-line therapy for NETs, because
the regimens used to date have not been effective as surgi-
cal treatments. Cisplatin used with etoposide, and strepto-
zocin used in combination with doxorubicin and 5-
fluorouracil, results in partial tumour response in more
than half of patients, as measured by radiologic and sero-
logic testing [26,27]. Targeted chemotherapy agents (for
example, everolimus, sunitinib) have been also used based
on improved progression-free survival. Continuous daily
administration of sunitinib at a dose of 37.5 mg improved
progression-free survival, overall survival and the objective
response rate as compared with placebo among patients
with advanced NETs. Everolimus, as compared with pla-
cebo, was associated with a 6.4-month prolongation of the
median progression-free survival [28,29]. Isolated metasta-
ses to the liver can be treated by radiofrequency ablation
or hepatic artery embolization, or by transarterial che-
moembolization, which combines hepatic artery
embolization with hepatic artery chemoinfusion [30]. Se-
lective internal radiation therapy for neuroendocrine me-
tastases to the liver delivers radioactive microsphere
therapy by injection directly into the hepatic artery [31].
In selected cases, a radionuclide therapy (yttrium-90- or
lutetium-177-labelled analogues, iodine-131-meta-iodo-
benzylguanidine) may also be considered [32].
The prognosis for, and long-term survival of, patients
with NETs has improved with the advent of more ag-
gressive surgical intervention and the use of long-acting
somatostatin agonists and targeted second-line therapy.
Recent studies have demonstrated that malignant dis-
ease, defined by direct invasion of adjacent organs by tu-
mours, lymph node metastases or distant organ spread,
may have 5-year survival rates as high as 77% to 95%
when treated aggressively with resection of primary tu-
mours and adjunctive therapy [33,34]. For localized and
well-differentiated tumours treated with complete surgi-
cal resection, 5-year survival approaches 90% for Meck-
el’s diverticulum NETs [35]. Favourable prognostic
factors include curative resection of the primary tumour,
absence of liver metastases and metachronous liver me-
tastases, and aggressive treatment of liver metastases
[36]. Unfortunately, nearly all patients with metastaticdisease have recurrence by the 7-year follow-up, even
after successful treatment [34].
In addition, surgery is the only curative modality for
localized colorectal cancer (stages I and II). Chemother-
apy is standard management for patients with high-risk
stage II, stage III or stage IV disease (capecitabine, 5-
fluorouracil, irinotecan, oxaliplatin). Biologic agents
(bevacizumab, cetuximab, panitumumab, regorafenib,
aflibercept) have assumed a major role in the treatment
of metastatic cases, with selection increasingly guided by
genetic analysis of the tumour. At present, the role of ra-
diation therapy is limited to palliative therapy for se-
lected metastatic sites, such as bone or brain [37-40].
All patients with synchronous colorectal cancer and
GEP-NETs must be extensively evaluated and clinically
monitored during the workup and follow-up period in
order to detect disease progression or relapse. Typically,
patients are seen every 3 to 6 months during the first
3 years and every 6 to 12 months thereafter. Routine la-
boratory tests, tumour markers (CEA, CA 19-9, CGA, 5-
hydroxyindoleacetic acid), endoscopic investigation of
the gastrointestinal tract, abdominal ultrasound, ultra-
sound of lymph nodes, chest radiography and CT or
whole-body PET/PET-CT scans may be used during
follow-up. We consider that early diagnosis with
complete preoperative examination, careful intraopera-
tive exploration, periodic postoperative surveillance and
radical resection can increase survival time. The treat-
ment strategy depends on many factors, such as the sur-
gical approach, the patient’s general condition, the
tumour grade, the extent of the disease and the patient’s
response to therapy. The treatment strategy needs to be
individualized for each patient [41,42]. However, all ma-
lignant tumours, because of their genomic instability,
have tremendous redundancy in their ability to maintain
growth and to spread into surrounding tissues and dis-
tant organs. This remarkable level of complexity makes
successful treatment of colon cancer coexisting with
GEP-NET all the more challenging.
Conclusions
The occurrence of synchronous primary cancers remains
an issue of great interest to surgeons, and oncologists in
particular, as well as the field of medicine in general.
The question of common genetic pathways in the patho-
genesis of such tumours is always raised when such as-
sociations are seen. Because multiple primary cancers
can no longer be considered rare, the physician should
be alert to the possibility of their occurrence. However,
NETs arising in a Meckel’s diverticulum represent a sig-
nificant clinical challenge because they have varied pre-
sentations, and initial imaging studies to locate the
tumour may be inconclusive. Our case addresses several
important aspects of clinical interest. First, only a very
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chronous GEP-NET within Meckel’s diverticulum and
colon adenocarcinoma. Second, there are no clear guide-
lines for appropriate treatment and follow-up of patients
with GEP-NET with a synchronous secondary malig-
nancy; therefore, our experience may help in the consid-
eration of treatment for similar patients. The case that
we report also emphasizes the importance of a thorough
exploration of the abdomen when carrying out elective
laparotomies. The impact of synchronously existing can-
cers on the overall prognosis of a patient must always be
considered when planning therapy in such instances as
well. Finally, patients who manifest multiple primary
cancers represent a unique experiment of nature that
may challenge new avenues of investigation into the
complex aetiology of tumours.
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